Review



anti igfbp2  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems anti igfbp2
    Anti Igfbp2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igfbp2/Mouse+IGFBP-2+Antibody/pmc13122697-270-10-13
    Average 93 stars, based on 9 article reviews
    anti igfbp2 - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Derivative Assay:

    Article Title: Secreted PGK1 and IGFBP2 contribute to the bystander effect of miR-10b gene editing in glioma
    Article Snippet: For experiments with the recombinant proteins, sequential dilutions of human recombinant proteins PGK1 (5455-PK-010, R&D Systems) and IGFBP2 (674-B2-025, R&D Systems) were prepared in the mixed fresh media and CM derived from naive glioma cells cultured for 5 days at a 3:7 ratio. .. For the rescue experiments, CM samples derived from the miR-10b-edited GSCs and the corresponding control cultures were incubated with 10 μg/mL IGFBP2-neutralizing antibody (R&D Systems, AF674) or control goat immunoglobulin G (IgG; Sigma) at 37°C for 4 h. The antibody has been removed from CM by using Dynabeads Protein G (Invitrogen, 10003D) via overnight rotation, and the CMs were used for culturing naive GSCs over 7 days. .. For PGK1 inhibition, CM samples were incubated with 10 μM PGK1 inhibitor CBR-470-1 (R&D Systems) , or DMSO at 37°C for 8 h. For RNase treatment, CMs derived from the miR-10b-edited GSC cultures were treated with RNase A (Affymetrix/USB 70194Y; 1:500 dilution) at 37°C for 5 min, and CMs were then used for culturing the recipient GCSs.

    Article Title: Secreted PGK1 and IGFBP2 contribute to the bystander effect of miR-10b gene editing in glioma
    Article Snippet: For experiments with the recombinant proteins, sequential dilutions of human recombinant proteins PGK1 (5455-PK-010, R&D Systems) and IGFBP2 (674-B2-025, R&D Systems) were prepared in the mixed fresh media and CM derived from naive glioma cells cultured for 5 days at a 3:7 ratio. .. For the rescue experiments, CM samples derived from the miR-10bedited GSCs and the corresponding control cultures were incubated with 10 mg/mL IGFBP2-neutralizing antibody (R&D Systems, AF674)55 or control goat immunoglobulin G (IgG; Sigma) at 37 C for 4 h. The antibody has been removed from CM by using Dynabeads Protein G (Invitrogen, 10003D) via overnight rotation, and the CMs were used for culturing naive GSCs over 7 days. .. For PGK1 inhibition, CM samples were incubated with 10 mM PGK1 inhibitor CBR-470-1 (R&D Systems)56,57 or DMSO at 37 C for 8 h. For RNase treatment, CMs derived from the miR-10b-edited GSC cul- 272 Molecular Therapy: Nucleic Acids Vol.

    Article Title: Secreted PGK1 and IGFBP2 contribute to the bystander effect of miR-10b gene editing in glioma.
    Article Snippet: Received 8 August 2022; accepted 31 December 2022; https://doi.org/10.1016/j.omtn.2022.12.018.. These authors contributed equally Correspondence: Anna M. Krichevsky, Ann Romney Center for Neurologic Diseases, Hale Building for Transformative Medicine, 60 Fenwood Rd, Room 9002T, Boston, MA 02115, USA.. E-mail: akrichevsky@bwh.harvard.edu MicroRNA-10b (miR-10b) is an essential glioma driver and one of the top candidates for targeted therapies for glioblastoma and other cancers.

    Control:

    Article Title: Secreted PGK1 and IGFBP2 contribute to the bystander effect of miR-10b gene editing in glioma
    Article Snippet: For experiments with the recombinant proteins, sequential dilutions of human recombinant proteins PGK1 (5455-PK-010, R&D Systems) and IGFBP2 (674-B2-025, R&D Systems) were prepared in the mixed fresh media and CM derived from naive glioma cells cultured for 5 days at a 3:7 ratio. .. For the rescue experiments, CM samples derived from the miR-10b-edited GSCs and the corresponding control cultures were incubated with 10 μg/mL IGFBP2-neutralizing antibody (R&D Systems, AF674) or control goat immunoglobulin G (IgG; Sigma) at 37°C for 4 h. The antibody has been removed from CM by using Dynabeads Protein G (Invitrogen, 10003D) via overnight rotation, and the CMs were used for culturing naive GSCs over 7 days. .. For PGK1 inhibition, CM samples were incubated with 10 μM PGK1 inhibitor CBR-470-1 (R&D Systems) , or DMSO at 37°C for 8 h. For RNase treatment, CMs derived from the miR-10b-edited GSC cultures were treated with RNase A (Affymetrix/USB 70194Y; 1:500 dilution) at 37°C for 5 min, and CMs were then used for culturing the recipient GCSs.

    Article Title: Secreted PGK1 and IGFBP2 contribute to the bystander effect of miR-10b gene editing in glioma
    Article Snippet: For experiments with the recombinant proteins, sequential dilutions of human recombinant proteins PGK1 (5455-PK-010, R&D Systems) and IGFBP2 (674-B2-025, R&D Systems) were prepared in the mixed fresh media and CM derived from naive glioma cells cultured for 5 days at a 3:7 ratio. .. For the rescue experiments, CM samples derived from the miR-10bedited GSCs and the corresponding control cultures were incubated with 10 mg/mL IGFBP2-neutralizing antibody (R&D Systems, AF674)55 or control goat immunoglobulin G (IgG; Sigma) at 37 C for 4 h. The antibody has been removed from CM by using Dynabeads Protein G (Invitrogen, 10003D) via overnight rotation, and the CMs were used for culturing naive GSCs over 7 days. .. For PGK1 inhibition, CM samples were incubated with 10 mM PGK1 inhibitor CBR-470-1 (R&D Systems)56,57 or DMSO at 37 C for 8 h. For RNase treatment, CMs derived from the miR-10b-edited GSC cul- 272 Molecular Therapy: Nucleic Acids Vol.

    Article Title: Age-Related Increases in IGFBP2 Increase Melanoma Cell Invasion and Lipid Synthesis
    Article Snippet: .. Tumors were allowed to grow, and treatment with rIgfbp2 (674-B2-025 from R&D Systems), Igfbp2-neutralizing antibody (AF674 from R&D Systems), or IgG control (AB-105-C from R&D Systems) was administered. rIGFBP2 experiments: young mice were injected intraperitoneally with 500 ng of rIgfbp2 in 100 μL of PBS every 2 days until tumors reach a maximum of 2,000 mm 3 . ..

    Article Title: Secreted PGK1 and IGFBP2 contribute to the bystander effect of miR-10b gene editing in glioma.
    Article Snippet: Received 8 August 2022; accepted 31 December 2022; https://doi.org/10.1016/j.omtn.2022.12.018.. These authors contributed equally Correspondence: Anna M. Krichevsky, Ann Romney Center for Neurologic Diseases, Hale Building for Transformative Medicine, 60 Fenwood Rd, Room 9002T, Boston, MA 02115, USA.. E-mail: akrichevsky@bwh.harvard.edu MicroRNA-10b (miR-10b) is an essential glioma driver and one of the top candidates for targeted therapies for glioblastoma and other cancers.

    Incubation:

    Article Title: Secreted PGK1 and IGFBP2 contribute to the bystander effect of miR-10b gene editing in glioma
    Article Snippet: For experiments with the recombinant proteins, sequential dilutions of human recombinant proteins PGK1 (5455-PK-010, R&D Systems) and IGFBP2 (674-B2-025, R&D Systems) were prepared in the mixed fresh media and CM derived from naive glioma cells cultured for 5 days at a 3:7 ratio. .. For the rescue experiments, CM samples derived from the miR-10b-edited GSCs and the corresponding control cultures were incubated with 10 μg/mL IGFBP2-neutralizing antibody (R&D Systems, AF674) or control goat immunoglobulin G (IgG; Sigma) at 37°C for 4 h. The antibody has been removed from CM by using Dynabeads Protein G (Invitrogen, 10003D) via overnight rotation, and the CMs were used for culturing naive GSCs over 7 days. .. For PGK1 inhibition, CM samples were incubated with 10 μM PGK1 inhibitor CBR-470-1 (R&D Systems) , or DMSO at 37°C for 8 h. For RNase treatment, CMs derived from the miR-10b-edited GSC cultures were treated with RNase A (Affymetrix/USB 70194Y; 1:500 dilution) at 37°C for 5 min, and CMs were then used for culturing the recipient GCSs.

    Article Title: Secreted PGK1 and IGFBP2 contribute to the bystander effect of miR-10b gene editing in glioma
    Article Snippet: For experiments with the recombinant proteins, sequential dilutions of human recombinant proteins PGK1 (5455-PK-010, R&D Systems) and IGFBP2 (674-B2-025, R&D Systems) were prepared in the mixed fresh media and CM derived from naive glioma cells cultured for 5 days at a 3:7 ratio. .. For the rescue experiments, CM samples derived from the miR-10bedited GSCs and the corresponding control cultures were incubated with 10 mg/mL IGFBP2-neutralizing antibody (R&D Systems, AF674)55 or control goat immunoglobulin G (IgG; Sigma) at 37 C for 4 h. The antibody has been removed from CM by using Dynabeads Protein G (Invitrogen, 10003D) via overnight rotation, and the CMs were used for culturing naive GSCs over 7 days. .. For PGK1 inhibition, CM samples were incubated with 10 mM PGK1 inhibitor CBR-470-1 (R&D Systems)56,57 or DMSO at 37 C for 8 h. For RNase treatment, CMs derived from the miR-10b-edited GSC cul- 272 Molecular Therapy: Nucleic Acids Vol.

    Article Title: IGFBP2 secretion by mammary adipocytes limits breast cancer invasion
    Article Snippet: Separation was performed by gel electrophoresis (Mini-PROTEAN TGX Precast Gels 4-20%, Bio-Rad, 4561096), before transferring onto a nitrocellulose membrane (Trans-Blot Turbo Transfer System, Bio-Rad) and blocking with AdvanBlock-Fluor (Advansta, R-03729-E10). .. Primary antibodies in AdvanBlock-Fluor were incubated overnight at 4°C; IGFBP2 (R&D Systems, AF674), IGF-II (Millipore, 05-166-MI), GAPDH (Hytest, 5G4MAB6C5), and GFP (Thermo Fisher Scientific, A11122). ..

    Article Title: IGFBP2 secretion by mammary adipocytes limits breast cancer invasion.
    Article Snippet: Separation was performed by gel electrophoresis (Mini-PROTEAN TGX Precast Gels 4-20%, Bio-Rad, 4561096), before transferring onto a nitrocellulose membrane (Trans-Blot Turbo Transfer System, Bio-Rad) and blocking with AdvanBlock-Fluor (Advansta, R-03729-E10). .. Primary antibodies in AdvanBlock-Fluor were incubated overnight at 4°C; IGFBP2 (R&D Systems, AF674), IGF-II (Millipore, 05-166-MI), GAPDH (Hytest, 5G4MAB6C5), and GFP (Thermo Fisher Scientific, A11122). ..

    Article Title: Secreted PGK1 and IGFBP2 contribute to the bystander effect of miR-10b gene editing in glioma.
    Article Snippet: Received 8 August 2022; accepted 31 December 2022; https://doi.org/10.1016/j.omtn.2022.12.018.. These authors contributed equally Correspondence: Anna M. Krichevsky, Ann Romney Center for Neurologic Diseases, Hale Building for Transformative Medicine, 60 Fenwood Rd, Room 9002T, Boston, MA 02115, USA.. E-mail: akrichevsky@bwh.harvard.edu MicroRNA-10b (miR-10b) is an essential glioma driver and one of the top candidates for targeted therapies for glioblastoma and other cancers.

    Recombinant:

    Article Title: IGFBP2 secretion by mammary adipocytes limits breast cancer invasion.
    Article Snippet: .. For the exogenous protein inverse invasion screen, cells were treated with either PBS or one of the following recombinant proteins (5 μM): SPARC (R&D Systems, 941-SP), DKK1 (R&D Systems, 5439-DK), DKK3 (R&D Systems, 1118-DK), TFPI (R&D Systems, 2974-PI), TFPI2 (R&D Systems, 2545-PI), HHIP (R&D Systems, 9280-HP), PAI1 (R&D Systems, 1786-PI), IGFBP2 (R&D Systems, 674-B2), IGFBP7 (R&D Systems, 1334-B7), and GSN (Novus, H00002934-Q01). .. For assessment of the IGF-II pathway perturbation, the following were used: recombinant IGF-II (10 ng/ml; R&D Systems, 292-G2), anti–IGF-II (10 μg/ml; Sigma-Aldrich, 05-166), or immunoglobulin G1κ (IgG1κ; 10 μg/ml; Sigma-Aldrich, M7894).

    Article Title: IGFBP2 secretion by mammary adipocytes limits breast cancer invasion
    Article Snippet: .. For the exogenous protein inverse invasion screen, cells were treated with either PBS or one of the following recombinant proteins (5 μM): SPARC (R&D Systems, 941-SP), DKK1 (R&D Systems, 5439-DK), DKK3 (R&D Systems, 1118-DK), TFPI (R&D Systems, 2974-PI), TFPI2 (R&D Systems, 2545-PI), HHIP (R&D Systems, 9280-HP), PAI1 (R&D Systems, 1786-PI), IGFBP2 (R&D Systems, 674-B2), IGFBP7 (R&D Systems, 1334-B7), and GSN (Novus, H00002934-Q01). .. For assessment of the IGF-II pathway perturbation, the following were used: recombinant IGF-II (10 ng/ml; R&D Systems, 292-G2), anti–IGF-II (10 μg/ml; Sigma-Aldrich, 05-166), or immunoglobulin G1κ (IgG1κ; 10 μg/ml; Sigma-Aldrich, M7894).

    Injection:

    Article Title: Age-Related Increases in IGFBP2 Increase Melanoma Cell Invasion and Lipid Synthesis
    Article Snippet: .. Tumors were allowed to grow, and treatment with rIgfbp2 (674-B2-025 from R&D Systems), Igfbp2-neutralizing antibody (AF674 from R&D Systems), or IgG control (AB-105-C from R&D Systems) was administered. rIGFBP2 experiments: young mice were injected intraperitoneally with 500 ng of rIgfbp2 in 100 μL of PBS every 2 days until tumors reach a maximum of 2,000 mm 3 . ..



    Similar Products

    recombinant igfbp2 protein  (MedChemExpress)
    93
    MedChemExpress recombinant igfbp2 protein
    Neuron-specific <t>Igfbp2</t> deficiency in the PFC induces cognitive dysfunction (A) Schematic of the experimental design. (B) Diagram of viral injection into the PFC (top) and representative image of viral expression (bottom); scale bars, 500 μm. (C) Representative western blot bands (top) and quantification of Igfbp2 protein levels in the PFC (bottom); n = 4 mice per group. (D) Schematic of the novel object recognition test, depicting the training phase (top) and the test phase (bottom). (E) Representative trajectory plots from the novel object recognition test. (F) Quantification of time spent investigating the novel object during the test phase; n = 8 mice per group. (G) Quantification of the number of investigations of the novel object during the test phase; n = 8 mice per group. (H) Schematic of the Y-maze test, depicting the training phase (top) and the test phase (bottom). (I) Representative trajectory plots from the Y-maze test. (J) Quantification of time spent in the novel arm during the test phase; n = 8 mice per group. (K) Quantification of the number of entries into the novel arm during the test phase; n = 8 mice per group. Analyzed by unpaired t test; ∗∗ p < 0.01. Data are presented as means ± SEM.
    Recombinant Igfbp2 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igfbp2/IGFBP-2%2C+Mouse/pmc13122697-235-0-3
    Average 93 stars, based on 1 article reviews
    recombinant igfbp2 protein - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    anti igfbp2  (R&D Systems)
    93
    R&D Systems anti igfbp2
    Neuron-specific <t>Igfbp2</t> deficiency in the PFC induces cognitive dysfunction (A) Schematic of the experimental design. (B) Diagram of viral injection into the PFC (top) and representative image of viral expression (bottom); scale bars, 500 μm. (C) Representative western blot bands (top) and quantification of Igfbp2 protein levels in the PFC (bottom); n = 4 mice per group. (D) Schematic of the novel object recognition test, depicting the training phase (top) and the test phase (bottom). (E) Representative trajectory plots from the novel object recognition test. (F) Quantification of time spent investigating the novel object during the test phase; n = 8 mice per group. (G) Quantification of the number of investigations of the novel object during the test phase; n = 8 mice per group. (H) Schematic of the Y-maze test, depicting the training phase (top) and the test phase (bottom). (I) Representative trajectory plots from the Y-maze test. (J) Quantification of time spent in the novel arm during the test phase; n = 8 mice per group. (K) Quantification of the number of entries into the novel arm during the test phase; n = 8 mice per group. Analyzed by unpaired t test; ∗∗ p < 0.01. Data are presented as means ± SEM.
    Anti Igfbp2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igfbp2/Mouse+IGFBP-2+Antibody/pmc13122697-270-10-13
    Average 93 stars, based on 1 article reviews
    anti igfbp2 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    human igfbp 2 elisa kit  (RayBiotech inc)
    94
    RayBiotech inc human igfbp 2 elisa kit
    Neuron-specific <t>Igfbp2</t> deficiency in the PFC induces cognitive dysfunction (A) Schematic of the experimental design. (B) Diagram of viral injection into the PFC (top) and representative image of viral expression (bottom); scale bars, 500 μm. (C) Representative western blot bands (top) and quantification of Igfbp2 protein levels in the PFC (bottom); n = 4 mice per group. (D) Schematic of the novel object recognition test, depicting the training phase (top) and the test phase (bottom). (E) Representative trajectory plots from the novel object recognition test. (F) Quantification of time spent investigating the novel object during the test phase; n = 8 mice per group. (G) Quantification of the number of investigations of the novel object during the test phase; n = 8 mice per group. (H) Schematic of the Y-maze test, depicting the training phase (top) and the test phase (bottom). (I) Representative trajectory plots from the Y-maze test. (J) Quantification of time spent in the novel arm during the test phase; n = 8 mice per group. (K) Quantification of the number of entries into the novel arm during the test phase; n = 8 mice per group. Analyzed by unpaired t test; ∗∗ p < 0.01. Data are presented as means ± SEM.
    Human Igfbp 2 Elisa Kit, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igfbp2/Human+IGFBP-2+ELISA/pm41996599-43-9-14
    Average 94 stars, based on 1 article reviews
    human igfbp 2 elisa kit - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    recombinant mouse igfbp2 rmigfbp2 protein  (MedChemExpress)
    93
    MedChemExpress recombinant mouse igfbp2 rmigfbp2 protein
    Neuron-specific <t>Igfbp2</t> deficiency in the PFC induces cognitive dysfunction (A) Schematic of the experimental design. (B) Diagram of viral injection into the PFC (top) and representative image of viral expression (bottom); scale bars, 500 μm. (C) Representative western blot bands (top) and quantification of Igfbp2 protein levels in the PFC (bottom); n = 4 mice per group. (D) Schematic of the novel object recognition test, depicting the training phase (top) and the test phase (bottom). (E) Representative trajectory plots from the novel object recognition test. (F) Quantification of time spent investigating the novel object during the test phase; n = 8 mice per group. (G) Quantification of the number of investigations of the novel object during the test phase; n = 8 mice per group. (H) Schematic of the Y-maze test, depicting the training phase (top) and the test phase (bottom). (I) Representative trajectory plots from the Y-maze test. (J) Quantification of time spent in the novel arm during the test phase; n = 8 mice per group. (K) Quantification of the number of entries into the novel arm during the test phase; n = 8 mice per group. Analyzed by unpaired t test; ∗∗ p < 0.01. Data are presented as means ± SEM.
    Recombinant Mouse Igfbp2 Rmigfbp2 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igfbp2/IGFBP-2%2C+Mouse/pm41964031-139-3-8
    Average 93 stars, based on 1 article reviews
    recombinant mouse igfbp2 rmigfbp2 protein - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    recombinant igfbp2  (R&D Systems)
    94
    R&D Systems recombinant igfbp2
    Neuron-specific <t>Igfbp2</t> deficiency in the PFC induces cognitive dysfunction (A) Schematic of the experimental design. (B) Diagram of viral injection into the PFC (top) and representative image of viral expression (bottom); scale bars, 500 μm. (C) Representative western blot bands (top) and quantification of Igfbp2 protein levels in the PFC (bottom); n = 4 mice per group. (D) Schematic of the novel object recognition test, depicting the training phase (top) and the test phase (bottom). (E) Representative trajectory plots from the novel object recognition test. (F) Quantification of time spent investigating the novel object during the test phase; n = 8 mice per group. (G) Quantification of the number of investigations of the novel object during the test phase; n = 8 mice per group. (H) Schematic of the Y-maze test, depicting the training phase (top) and the test phase (bottom). (I) Representative trajectory plots from the Y-maze test. (J) Quantification of time spent in the novel arm during the test phase; n = 8 mice per group. (K) Quantification of the number of entries into the novel arm during the test phase; n = 8 mice per group. Analyzed by unpaired t test; ∗∗ p < 0.01. Data are presented as means ± SEM.
    Recombinant Igfbp2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igfbp2/Recombinant+Human+IGFBP-2+Protein%2C+CF/bio_rxiv__64898__2026__02__19__706859-246-36-38
    Average 94 stars, based on 1 article reviews
    recombinant igfbp2 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti igfbp2  (Proteintech)
    94
    Proteintech anti igfbp2
    Neuron-specific <t>Igfbp2</t> deficiency in the PFC induces cognitive dysfunction (A) Schematic of the experimental design. (B) Diagram of viral injection into the PFC (top) and representative image of viral expression (bottom); scale bars, 500 μm. (C) Representative western blot bands (top) and quantification of Igfbp2 protein levels in the PFC (bottom); n = 4 mice per group. (D) Schematic of the novel object recognition test, depicting the training phase (top) and the test phase (bottom). (E) Representative trajectory plots from the novel object recognition test. (F) Quantification of time spent investigating the novel object during the test phase; n = 8 mice per group. (G) Quantification of the number of investigations of the novel object during the test phase; n = 8 mice per group. (H) Schematic of the Y-maze test, depicting the training phase (top) and the test phase (bottom). (I) Representative trajectory plots from the Y-maze test. (J) Quantification of time spent in the novel arm during the test phase; n = 8 mice per group. (K) Quantification of the number of entries into the novel arm during the test phase; n = 8 mice per group. Analyzed by unpaired t test; ∗∗ p < 0.01. Data are presented as means ± SEM.
    Anti Igfbp2, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igfbp2/IGFBP2+Antibody/10__1097_slash_js9__0000000000004351-139-23-24
    Average 94 stars, based on 1 article reviews
    anti igfbp2 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti igfbp2  (ABclonal Biotechnology)
    94
    ABclonal Biotechnology anti igfbp2
    Neuron-specific <t>Igfbp2</t> deficiency in the PFC induces cognitive dysfunction (A) Schematic of the experimental design. (B) Diagram of viral injection into the PFC (top) and representative image of viral expression (bottom); scale bars, 500 μm. (C) Representative western blot bands (top) and quantification of Igfbp2 protein levels in the PFC (bottom); n = 4 mice per group. (D) Schematic of the novel object recognition test, depicting the training phase (top) and the test phase (bottom). (E) Representative trajectory plots from the novel object recognition test. (F) Quantification of time spent investigating the novel object during the test phase; n = 8 mice per group. (G) Quantification of the number of investigations of the novel object during the test phase; n = 8 mice per group. (H) Schematic of the Y-maze test, depicting the training phase (top) and the test phase (bottom). (I) Representative trajectory plots from the Y-maze test. (J) Quantification of time spent in the novel arm during the test phase; n = 8 mice per group. (K) Quantification of the number of entries into the novel arm during the test phase; n = 8 mice per group. Analyzed by unpaired t test; ∗∗ p < 0.01. Data are presented as means ± SEM.
    Anti Igfbp2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igfbp2/IGFBP2+Rabbit+pAb/10__1097_slash_js9__0000000000004351-124-27-28
    Average 94 stars, based on 1 article reviews
    anti igfbp2 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti igfbp2 antibody  (R&D Systems)
    94
    R&D Systems anti igfbp2 antibody
    Neuron-specific <t>Igfbp2</t> deficiency in the PFC induces cognitive dysfunction (A) Schematic of the experimental design. (B) Diagram of viral injection into the PFC (top) and representative image of viral expression (bottom); scale bars, 500 μm. (C) Representative western blot bands (top) and quantification of Igfbp2 protein levels in the PFC (bottom); n = 4 mice per group. (D) Schematic of the novel object recognition test, depicting the training phase (top) and the test phase (bottom). (E) Representative trajectory plots from the novel object recognition test. (F) Quantification of time spent investigating the novel object during the test phase; n = 8 mice per group. (G) Quantification of the number of investigations of the novel object during the test phase; n = 8 mice per group. (H) Schematic of the Y-maze test, depicting the training phase (top) and the test phase (bottom). (I) Representative trajectory plots from the Y-maze test. (J) Quantification of time spent in the novel arm during the test phase; n = 8 mice per group. (K) Quantification of the number of entries into the novel arm during the test phase; n = 8 mice per group. Analyzed by unpaired t test; ∗∗ p < 0.01. Data are presented as means ± SEM.
    Anti Igfbp2 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igfbp2/Human+IGFBP-2+Antibody/pm41620401-74-10-13
    Average 94 stars, based on 1 article reviews
    anti igfbp2 antibody - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Neuron-specific Igfbp2 deficiency in the PFC induces cognitive dysfunction (A) Schematic of the experimental design. (B) Diagram of viral injection into the PFC (top) and representative image of viral expression (bottom); scale bars, 500 μm. (C) Representative western blot bands (top) and quantification of Igfbp2 protein levels in the PFC (bottom); n = 4 mice per group. (D) Schematic of the novel object recognition test, depicting the training phase (top) and the test phase (bottom). (E) Representative trajectory plots from the novel object recognition test. (F) Quantification of time spent investigating the novel object during the test phase; n = 8 mice per group. (G) Quantification of the number of investigations of the novel object during the test phase; n = 8 mice per group. (H) Schematic of the Y-maze test, depicting the training phase (top) and the test phase (bottom). (I) Representative trajectory plots from the Y-maze test. (J) Quantification of time spent in the novel arm during the test phase; n = 8 mice per group. (K) Quantification of the number of entries into the novel arm during the test phase; n = 8 mice per group. Analyzed by unpaired t test; ∗∗ p < 0.01. Data are presented as means ± SEM.

    Journal: iScience

    Article Title: Neuronal Igfbp2 deficiency in the prefrontal cortex impairs cognition through synaptic dysfunction in male mice

    doi: 10.1016/j.isci.2026.115629

    Figure Lengend Snippet: Neuron-specific Igfbp2 deficiency in the PFC induces cognitive dysfunction (A) Schematic of the experimental design. (B) Diagram of viral injection into the PFC (top) and representative image of viral expression (bottom); scale bars, 500 μm. (C) Representative western blot bands (top) and quantification of Igfbp2 protein levels in the PFC (bottom); n = 4 mice per group. (D) Schematic of the novel object recognition test, depicting the training phase (top) and the test phase (bottom). (E) Representative trajectory plots from the novel object recognition test. (F) Quantification of time spent investigating the novel object during the test phase; n = 8 mice per group. (G) Quantification of the number of investigations of the novel object during the test phase; n = 8 mice per group. (H) Schematic of the Y-maze test, depicting the training phase (top) and the test phase (bottom). (I) Representative trajectory plots from the Y-maze test. (J) Quantification of time spent in the novel arm during the test phase; n = 8 mice per group. (K) Quantification of the number of entries into the novel arm during the test phase; n = 8 mice per group. Analyzed by unpaired t test; ∗∗ p < 0.01. Data are presented as means ± SEM.

    Article Snippet: Recombinant Igfbp2 protein (MCE; Cat# HY- P74846 ) was dissolved in sterile saline at 10 μg/μL.

    Techniques: Injection, Expressing, Western Blot

    Neuron-specific Igfbp2 deficiency in the PFC reduces excitatory synaptic transmission and neuronal excitability (A) Representative traces of sEPSC recorded from PFC neurons in AAV-scramble (top) and AAV-shRNA (bottom) groups. (B) Cumulative probability plots (main panel) and quantification (insert panel) of sEPSC frequency in AAV-Scramble and AAV-shRNA groups. (C) Cumulative probability plots (main panel) and quantification (insert panel) of sEPSC amplitude in AAV-Scramble and AAV-shRNA groups. (D) Representative traces of sIPSC recorded from PFC neurons in AAV-Scramble (top) and AAV-shRNA (bottom) groups. (E) Cumulative probability plots (main panel) and quantification (insert panel) of sIPSC frequency in AAV-Scramble and AAV-shRNA groups. (F) Cumulative probability plots (main panel) and quantification (insert panel) of sIPSC amplitude in AAV-Scramble and AAV-shRNA groups. (G) Representative traces of AP elicited by 200 pA current injections in PFC neurons from AAV-Scramble (left) and AAV-shRNA (right) groups. (H) Quantification of AP firing frequency in response to a range of current injections in PFC neurons from AAV-Scramble and AAV-shRNA groups. Analyzed by unpaired t test in B, C, E, and F, and two-way repeated-measure ANOVA in H; n = 8 neurons from 4 mice per group; ns: not significant, ∗∗ p < 0.01. Data are presented as means ± SEM.

    Journal: iScience

    Article Title: Neuronal Igfbp2 deficiency in the prefrontal cortex impairs cognition through synaptic dysfunction in male mice

    doi: 10.1016/j.isci.2026.115629

    Figure Lengend Snippet: Neuron-specific Igfbp2 deficiency in the PFC reduces excitatory synaptic transmission and neuronal excitability (A) Representative traces of sEPSC recorded from PFC neurons in AAV-scramble (top) and AAV-shRNA (bottom) groups. (B) Cumulative probability plots (main panel) and quantification (insert panel) of sEPSC frequency in AAV-Scramble and AAV-shRNA groups. (C) Cumulative probability plots (main panel) and quantification (insert panel) of sEPSC amplitude in AAV-Scramble and AAV-shRNA groups. (D) Representative traces of sIPSC recorded from PFC neurons in AAV-Scramble (top) and AAV-shRNA (bottom) groups. (E) Cumulative probability plots (main panel) and quantification (insert panel) of sIPSC frequency in AAV-Scramble and AAV-shRNA groups. (F) Cumulative probability plots (main panel) and quantification (insert panel) of sIPSC amplitude in AAV-Scramble and AAV-shRNA groups. (G) Representative traces of AP elicited by 200 pA current injections in PFC neurons from AAV-Scramble (left) and AAV-shRNA (right) groups. (H) Quantification of AP firing frequency in response to a range of current injections in PFC neurons from AAV-Scramble and AAV-shRNA groups. Analyzed by unpaired t test in B, C, E, and F, and two-way repeated-measure ANOVA in H; n = 8 neurons from 4 mice per group; ns: not significant, ∗∗ p < 0.01. Data are presented as means ± SEM.

    Article Snippet: Recombinant Igfbp2 protein (MCE; Cat# HY- P74846 ) was dissolved in sterile saline at 10 μg/μL.

    Techniques: Transmission Assay, shRNA

    Neuron-specific Igfbp2 deficiency in the PFC disrupts synaptic integrity (A) Representative images of dendritic spines in the PFC from AAV-Scramble (left) and AAV-shRNA (right) groups; scale bars, 10 μm. (B) Quantification of dendritic spine density (number per 10 μm) in the PFC from AAV-Scramble and AAV-shRNA groups; n = 9 brain sections from 3 mice per group. (C) Representative western blot bands (top) and quantification of synapsin-1 protein levels (bottom) in the PFC from AAV-scramble and AAV-shRNA groups; n = 4 mice per group. (D) Representative western blot bands (top) and quantification of PSD-95 protein levels (bottom) in the PFC from AAV-Scramble and AAV-shRNA groups; n = 4 mice per group. Analyzed by unpaired t test; ∗ p < 0.05 and ∗∗∗ p < 0.001. Data are presented as means ± SEM.

    Journal: iScience

    Article Title: Neuronal Igfbp2 deficiency in the prefrontal cortex impairs cognition through synaptic dysfunction in male mice

    doi: 10.1016/j.isci.2026.115629

    Figure Lengend Snippet: Neuron-specific Igfbp2 deficiency in the PFC disrupts synaptic integrity (A) Representative images of dendritic spines in the PFC from AAV-Scramble (left) and AAV-shRNA (right) groups; scale bars, 10 μm. (B) Quantification of dendritic spine density (number per 10 μm) in the PFC from AAV-Scramble and AAV-shRNA groups; n = 9 brain sections from 3 mice per group. (C) Representative western blot bands (top) and quantification of synapsin-1 protein levels (bottom) in the PFC from AAV-scramble and AAV-shRNA groups; n = 4 mice per group. (D) Representative western blot bands (top) and quantification of PSD-95 protein levels (bottom) in the PFC from AAV-Scramble and AAV-shRNA groups; n = 4 mice per group. Analyzed by unpaired t test; ∗ p < 0.05 and ∗∗∗ p < 0.001. Data are presented as means ± SEM.

    Article Snippet: Recombinant Igfbp2 protein (MCE; Cat# HY- P74846 ) was dissolved in sterile saline at 10 μg/μL.

    Techniques: shRNA, Western Blot

    Exogenous supplementation of Igfbp2 in the PFC rescues cognitive deficits induced by neuron-specific Igfbp2 deficiency (A) Schematic of the experimental design. (B) Diagram shows virus injection and cannula placement into the PFC (top), and a representative image of cannula position and viral expression in the PFC (bottom); scale bars, 500 μm. (C) Representative western blot bands (top) and quantification of Igfbp2 protein levels in the PFC (bottom); n = 4 mice per group. (D) Schematic of the novel object recognition test, depicting the training phase (top) and the test phase (bottom). (E) Representative trajectory plots from the novel object recognition test. (F) Quantification of time spent investigating the novel object during the test phase; n = 8 mice per group. (G) Quantification of the number of investigations of the novel object during the test phase; n = 8 mice per group. (H) Schematic of the Y-maze test, depicting the training phase (top) and the test phase (bottom). (I) Representative trajectory plots from the Y-maze test. (J) Quantification of time spent in the novel arm during the test phase; n = 8 mice per group. (K) Quantification of the number of entries into the novel arm during the test phase; n = 8 mice per group. Analyzed by unpaired t test; ∗∗ p < 0.01. Data are presented as means ± SEM.

    Journal: iScience

    Article Title: Neuronal Igfbp2 deficiency in the prefrontal cortex impairs cognition through synaptic dysfunction in male mice

    doi: 10.1016/j.isci.2026.115629

    Figure Lengend Snippet: Exogenous supplementation of Igfbp2 in the PFC rescues cognitive deficits induced by neuron-specific Igfbp2 deficiency (A) Schematic of the experimental design. (B) Diagram shows virus injection and cannula placement into the PFC (top), and a representative image of cannula position and viral expression in the PFC (bottom); scale bars, 500 μm. (C) Representative western blot bands (top) and quantification of Igfbp2 protein levels in the PFC (bottom); n = 4 mice per group. (D) Schematic of the novel object recognition test, depicting the training phase (top) and the test phase (bottom). (E) Representative trajectory plots from the novel object recognition test. (F) Quantification of time spent investigating the novel object during the test phase; n = 8 mice per group. (G) Quantification of the number of investigations of the novel object during the test phase; n = 8 mice per group. (H) Schematic of the Y-maze test, depicting the training phase (top) and the test phase (bottom). (I) Representative trajectory plots from the Y-maze test. (J) Quantification of time spent in the novel arm during the test phase; n = 8 mice per group. (K) Quantification of the number of entries into the novel arm during the test phase; n = 8 mice per group. Analyzed by unpaired t test; ∗∗ p < 0.01. Data are presented as means ± SEM.

    Article Snippet: Recombinant Igfbp2 protein (MCE; Cat# HY- P74846 ) was dissolved in sterile saline at 10 μg/μL.

    Techniques: Virus, Injection, Expressing, Western Blot

    Exogenous supplementation of Igfbp2 in the PFC restores excitatory synaptic transmission and neuronal excitability impaired by neuron-specific Igfbp2 deficiency (A) Representative traces of sEPSC recorded from PFC neurons in saline (top) and Igfbp2 (bottom) groups. (B) Cumulative probability plots (main panel) and quantification (insert panel) of sEPSC frequency in saline (top) and Igfbp2 (bottom) groups. (C) Cumulative probability plots (main panel) and quantification (insert panel) of sEPSC amplitude in saline and Igfbp2 groups. (D) Representative traces of sIPSC recorded from PFC neurons in saline (top) and Igfbp2 (bottom) groups. (E) Cumulative probability plots (main panel) and quantification (insert panel) of sIPSC frequency in saline and Igfbp2 groups. (F) Cumulative probability plots (main panel) and quantification (insert panel) of sIPSC amplitude in saline and Igfbp2 groups. (G) Representative traces of AP elicited by 200 pA current injections in PFC neurons from saline (left) and Igfbp2 (right) groups. (H) Quantification of AP firing frequency in response to a range of current injections in PFC neurons from Saline (left) and Igfbp2 (right) groups. Analyzed by unpaired t test in B, C, E, and F, and two-way repeated-measure ANOVA in H; n = 8 neurons from 4 mice per group; ns: not significant, ∗∗ p < 0.01. Data are presented as means ± SEM.

    Journal: iScience

    Article Title: Neuronal Igfbp2 deficiency in the prefrontal cortex impairs cognition through synaptic dysfunction in male mice

    doi: 10.1016/j.isci.2026.115629

    Figure Lengend Snippet: Exogenous supplementation of Igfbp2 in the PFC restores excitatory synaptic transmission and neuronal excitability impaired by neuron-specific Igfbp2 deficiency (A) Representative traces of sEPSC recorded from PFC neurons in saline (top) and Igfbp2 (bottom) groups. (B) Cumulative probability plots (main panel) and quantification (insert panel) of sEPSC frequency in saline (top) and Igfbp2 (bottom) groups. (C) Cumulative probability plots (main panel) and quantification (insert panel) of sEPSC amplitude in saline and Igfbp2 groups. (D) Representative traces of sIPSC recorded from PFC neurons in saline (top) and Igfbp2 (bottom) groups. (E) Cumulative probability plots (main panel) and quantification (insert panel) of sIPSC frequency in saline and Igfbp2 groups. (F) Cumulative probability plots (main panel) and quantification (insert panel) of sIPSC amplitude in saline and Igfbp2 groups. (G) Representative traces of AP elicited by 200 pA current injections in PFC neurons from saline (left) and Igfbp2 (right) groups. (H) Quantification of AP firing frequency in response to a range of current injections in PFC neurons from Saline (left) and Igfbp2 (right) groups. Analyzed by unpaired t test in B, C, E, and F, and two-way repeated-measure ANOVA in H; n = 8 neurons from 4 mice per group; ns: not significant, ∗∗ p < 0.01. Data are presented as means ± SEM.

    Article Snippet: Recombinant Igfbp2 protein (MCE; Cat# HY- P74846 ) was dissolved in sterile saline at 10 μg/μL.

    Techniques: Transmission Assay, Saline

    Exogenous supplementation of Igfbp2 in the PFC restores synaptic integrity disrupted by neuron-specific Igfbp2 deficiency (A) Representative images of dendritic spines in the PFC from saline (left) and Igfbp2 (right) groups; scale bars, 10 μm. (B) Quantification of dendritic spine density (number per 10 μm) in the PFC from saline and Igfbp2 groups; n = 9 brain sections from 3 mice per group. (C) Representative western blot bands (top) and quantification of synapsin-1 protein levels (bottom) in the PFC from AAV-Scramble and AAV-shRNA groups; n = 4 mice per group. (D) Representative western blot bands (top) and quantification of PSD-95 protein levels (bottom) in the PFC from AAV-Scramble and AAV-shRNA groups; n = 4 mice per group. Analyzed by unpaired t test; ∗ p < 0.05 and ∗∗∗ p < 0.001. Data are presented as means ± SEM.

    Journal: iScience

    Article Title: Neuronal Igfbp2 deficiency in the prefrontal cortex impairs cognition through synaptic dysfunction in male mice

    doi: 10.1016/j.isci.2026.115629

    Figure Lengend Snippet: Exogenous supplementation of Igfbp2 in the PFC restores synaptic integrity disrupted by neuron-specific Igfbp2 deficiency (A) Representative images of dendritic spines in the PFC from saline (left) and Igfbp2 (right) groups; scale bars, 10 μm. (B) Quantification of dendritic spine density (number per 10 μm) in the PFC from saline and Igfbp2 groups; n = 9 brain sections from 3 mice per group. (C) Representative western blot bands (top) and quantification of synapsin-1 protein levels (bottom) in the PFC from AAV-Scramble and AAV-shRNA groups; n = 4 mice per group. (D) Representative western blot bands (top) and quantification of PSD-95 protein levels (bottom) in the PFC from AAV-Scramble and AAV-shRNA groups; n = 4 mice per group. Analyzed by unpaired t test; ∗ p < 0.05 and ∗∗∗ p < 0.001. Data are presented as means ± SEM.

    Article Snippet: Recombinant Igfbp2 protein (MCE; Cat# HY- P74846 ) was dissolved in sterile saline at 10 μg/μL.

    Techniques: Saline, Western Blot, shRNA

    Schematic summary of this study Neuron-specific Igfbp2 deficiency in the PFC impairs cognitive function by disrupting synaptic integrity, excitatory transmission, and neuronal activity, whereas exogenous Igfbp2 supplementation mitigates cognitive deficits by restoring synaptic integrity, excitatory transmission, and neuronal activity. PFC prefrontal cortex, sEPSC spontaneous excitatory postsynaptic currents, Igfbp2 insulin-like growth factor-binding protein 2.

    Journal: iScience

    Article Title: Neuronal Igfbp2 deficiency in the prefrontal cortex impairs cognition through synaptic dysfunction in male mice

    doi: 10.1016/j.isci.2026.115629

    Figure Lengend Snippet: Schematic summary of this study Neuron-specific Igfbp2 deficiency in the PFC impairs cognitive function by disrupting synaptic integrity, excitatory transmission, and neuronal activity, whereas exogenous Igfbp2 supplementation mitigates cognitive deficits by restoring synaptic integrity, excitatory transmission, and neuronal activity. PFC prefrontal cortex, sEPSC spontaneous excitatory postsynaptic currents, Igfbp2 insulin-like growth factor-binding protein 2.

    Article Snippet: Recombinant Igfbp2 protein (MCE; Cat# HY- P74846 ) was dissolved in sterile saline at 10 μg/μL.

    Techniques: Transmission Assay, Activity Assay, Binding Assay